All the news Showing 10 of 15 articles from: AASLD 2019Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatocellular carcinoma (HCC) A healthy lifestyle could prevent most liver cancer and liver-related deaths Liz Highleyman / 17 December 2019 A healthy lifestyle, including smoking cessation, moderate drinking, a balanced diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer and deaths due to liver disease, according to a study ... Hepatitis delta Combination therapies show promise against hepatitis D Liz Highleyman / 16 December 2019 Combination regimens using lonafarnib or bulevirtide reduced levels of hepatitis delta virus (HDV) in a majority of people with HDV and hepatitis B virus (HBV) co-infection, researchers reported at the AASLD Liver Meeting ... Hepatitis C elimination The U.S. needs extra action to eliminate viral hepatitis, the nation’s deadliest infectious disease STAT / 11 December 2019 Models of care ‘Building bridges’ between PCPs, liver specialists for HCV led to 100% cure Healio / 11 December 2019 NAFLD Global burden of deaths and liver cancer due to non-alcoholic fatty liver disease growing Keith Alcorn / 11 December 2019 Non-alcoholic fatty liver disease is a growing cause of liver cancer and death in some regions of the world, an analysis of global reporting on liver disease shows. The findings ... Hepatocellular carcinoma (HCC) Immunotherapy combination improves liver cancer survival Liz Highleyman / 27 November 2019 A combination of nivolumab (Opdivo) and ipilimumab (Yervoy), two different types of checkpoint inhibitor immunotherapy, led to higher response rates and longer survival than nivolumab alone in people with advanced liver cancer, according to a ... Experimental treatments for NASH/NAFLD New NASH therapies show promise in mid-stage studies Liz Highleyman / 26 November 2019 Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ... NAFLD People with fatty liver disease struggle to lose weight Liz Highleyman / 25 November 2019 Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can succeed and doing so improves liver health, according to studies ... Hepatocellular carcinoma (HCC) Sustained response to HCV antivirals boosts liver cancer survival Liz Highleyman / 19 November 2019 People with liver cancer who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy for hepatitis C saw a reduction in both liver-related and all-cause mortality over five years, according to ... Hepatocellular carcinoma (HCC) Hepatitis B antiviral drugs reduce liver cancer risk Liz Highleyman / 19 November 2019 Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive